Minds From Another Planet…Talking About This One!

Jeff Aronin is Changing the Biosciences

Paragon Biosciences seeks to connect portfolio companies with cutting-edge resources and dedicated experts in order to create medical solutions. Paragon begins by identifying the highest patient need with the lowest treatment availability. They then pick people and ideas they believe will yield the most successful results. To meet the identified need, they create companies. They then provide capital and resources in a manner that creates a sustainable business model for all those invested, including the patients. Healthcare industry leaders, as well as biotech entrepreneurs, manage Paragon’s portfolio, greatly improving patient outcomes. In fact, we have had 13 new medicines approved by the FDA in the past decade.

Jeff Aronin has been CEO and Chairman at Paragon Biosciences since 2010. In addition, he has also been CEO of several companies that are part of Paragon’s portfolio, including Harmony Biosciences and Castle Creek Pharmaceuticals. Before becoming CEO of Paragon, Jeff Aronin was CEO and president at Ovation Pharmaceuticals, Inc., which he founded in 2000. Lundbeck, Inc. acquired Ovation in 2009, during which time Mr. Aronin served as CEO of Lundbeck. In December of 2009, he stepped down as CEO and became Lundbeck’s Strategic Advisor.

Jeff Aronin received his M.B.A. from DePaul University and a B.S. from Northern Illinois University (http://www.worldbusinesschicago.com/profile/jeff-aronin/). He has the privilege of being named as one of the future leaders of the industry by Pharmaceutical Executive as well as one of the most inspirational leaders in pharma by PharmaVOICE. He has been the recipient of Ernst & Young’s Entrepreneur of the Year Award. He also is in the Illinois Entrepreneur Hall of Fame. His success is of little surprise since he has spent over 20 years successfully leading both private and public pharmaceutical companies. Jeff Aronin further experience in mergers and acquisitions has also proven invaluable as he as furthered the biotech industry.